Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Change in Cash (2016 - 2025)

Apyx Medical (APYX) has disclosed Change in Cash for 15 consecutive years, with $6.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Cash rose 77.17% year-over-year to $6.6 million, compared with a TTM value of -$1000.0 through Dec 2025, up 99.99%, and an annual FY2025 reading of -$1000.0, up 99.99% over the prior year.
  • Change in Cash was $6.6 million for Q4 2025 at Apyx Medical, up from -$4.2 million in the prior quarter.
  • Across five years, Change in Cash topped out at $21.5 million in Q4 2023 and bottomed at -$6.4 million in Q1 2024.
  • Average Change in Cash over 5 years is -$508750.0, with a median of -$3.1 million recorded in 2021.
  • The sharpest move saw Change in Cash plummeted 16475.0% in 2022, then surged 563.65% in 2023.
  • Year by year, Change in Cash stood at -$28000.0 in 2021, then tumbled by 16475.0% to -$4.6 million in 2022, then soared by 563.65% to $21.5 million in 2023, then tumbled by 82.67% to $3.7 million in 2024, then surged by 77.17% to $6.6 million in 2025.
  • Business Quant data shows Change in Cash for APYX at $6.6 million in Q4 2025, -$4.2 million in Q3 2025, and -$1.7 million in Q2 2025.